Ongentys (Opicapone) is a selective and reversible catechol-O-methyltransferase inhibitor. Used as an adjunctive treatment to levodopa/carbidopa, it is indicated for improving "off" episodes in patients with Parkinson's disease.

How to Use Ongentys (Opicapone)

Administration Timing and Frequency

Recommended regimen: Take orally once daily, before bedtime.

Fasting requirement: Fasting is required for 1 hour before and after taking the medication to ensure that drug absorption is not affected by food.

Combination with Levodopa

Ongentys must be used in combination with a fixed dose of levodopa/carbidopa and cannot be administered alone.

If a dose is missed, do not make up for it; continue administration at the originally scheduled time on the next day.

Precautions for Discontinuation

Sudden discontinuation may lead to withdrawal-induced hyperpyrexia or confusion. The dose must be reduced gradually, and the patient's response should be monitored.

Dose Adjustment of Ongentys (Opicapone)

Adjustment for Patients with Hepatic Impairment

Mild impairment (Child-Pugh Class A): No dose adjustment is required.

Moderate impairment (Child-Pugh Class B): Reduce the dose to 25 mg per day.

Severe impairment (Child-Pugh Class C): Contraindicated.

Adjustment for Patients with Renal Impairment

No dose adjustment is required for patients with mild to moderate renal impairment.

End-stage renal disease (ESRD, creatinine clearance < 15 mL/min): Avoid use.

Elderly Patients

No dose adjustment is required, but caution should be exercised regarding the increased sensitivity of elderly patients to adverse reactions.

Precautions for Ongentys (Opicapone) Use in Special Populations

Pregnant and Lactating Women

Pregnant women: Animal studies have shown embryotoxicity; use only when the benefit is clearly established.

Lactating women: Human data are insufficient; it is recommended to weigh the necessity of breastfeeding.

Drug Interactions

Contraindicated combinations: Non-selective monoamine oxidase inhibitors (MAOIs).

Drugs requiring caution: Drugs metabolized by catechol-O-methyltransferase (e.g., epinephrine, dopamine), which may cause arrhythmias or blood pressure fluctuations.